<DOC>
	<DOCNO>NCT00961181</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy paclitaxel release balloon patient in-stent restenosis coronary artery .</brief_summary>
	<brief_title>Paclitaxel Releasing Balloon Patients Presenting With In-Stent Restenosis</brief_title>
	<detailed_description>All patient treat paclitaxel release balloon Pantera Lux . The indication in-stent restenosis either bare metal stent ( BMS ) drug elute stent ( DES ) . Clinical follow visit 1 , 6 12 month . Angiographic follow visit 6 month .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patient &gt; /= 18 year 2 . Written patient informed consent available 3 . Patients stable , unstable document silent angina pectoris 4 . Patient eligible percutaneous coronary intervention 5 . Patient acceptable candidate coronary artery bypass surgery 6 . Patients single restenotic lesion previously stented area coronary artery ( irrelevant whether BMS DES relate ) 7 . Target reference vessel diameter ( visual estimation ) : 2 4 mm 8 . Target lesion length ( visual estimation ) : 8 28 mm 9 . Target lesion stenosis ( visual estimation ) : &gt; /= 50 % &lt; 100 % 1 . Left ventricular ejection fraction &lt; 30 % 2 . Visible thrombus target vessel visualize angiography 3 . Myocardial infarction ( STEMI/NSTEMI ) within 72 hour intend treatment . Determination CKMB and/or troponin T I require . Notes : Laboratory assessment do within 24 hour prior intervention . Patients CKMB and/or troponin T I &gt; 2 fold upper limit normal must include trial . 4 . Patients plan major surgery within 3 month plan coronary intervention and/or risk either acetylsalicylic acid clopidogrel cessation 5 . Lesion length longer length available treatment balloon 6 . Impaired renal function ( serum creatinine &gt; 2.0mg/dl 177 micro mol/l , determine within 72 hour prior intervention ) 7 . Additional coronary lesion ( restenotic de novo ) vessel require treatment 8 . Totally occluded coronary artery ( Mehran classification IV TIMI flow 0 ) 9 . Target lesion locate vessel bifurcation 10 . Previous and/or plan brachytherapy target vessel 11 . Target lesion locate leave main coronary artery 12 . Stroke TIA &lt; 6 month prior procedure 13 . Patient sign cardiogenic shock 14 . Patient ongoing systemic immunosuppressive therapy paclitaxel agent limus group ( i.e . sirolimus , tacrolimus , everolimus ) 15 . Surgeries kind within 30 day prior screen 16 . Patient bleed diathesis anticoagulation antiplatelet medication contraindicate 17 . Known allergy antiplatelet , anticoagulation therapy , contrast medium paclitaxel 18 . Pregnant and/or breastfeed female female intend become pregnant ( pregnancy test require female childbearing potential ) 19 . Patient life expectancy le one year 20 . Patient currently enrol investigational device drug trial 21 . Patient known incompliance medical ( antiplatelet , anticoagulation ) therapy 22 . Patient able willing adhere followup visit include followup angiography</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>in-stent restenosis</keyword>
	<keyword>BMS-ISR</keyword>
	<keyword>DES-ISR</keyword>
	<keyword>drug elute balloon</keyword>
</DOC>